SightGlass DOT Myopia Control Lenses Show No Link to Astigmatism

Why It Matters

The results reassure eye‑care professionals that DOT lenses can safely control myopia without worsening astigmatism, expanding treatment options in a market seeking both efficacy and refractive stability.

Key Takeaways

• DOT lenses did not increase astigmatism after 12 months.
• North American and Chinese trials showed similar myopia‑control efficacy.
• Axial length reduced by 0.15 mm (NA) and 0.29 mm (China).
• Contrast‑modulation mechanism differs from peripheral‑defocus designs.
• Findings reassure clinicians about DOT safety for children.

Pulse Analysis

The global rise in childhood myopia has driven rapid innovation in optical interventions, from peripheral‑defocus spectacles to orthokeratology lenses. While these approaches effectively slow axial elongation, several clinical reports have hinted that altering peripheral optics may inadvertently increase corneal astigmatism, creating a trade‑off that worries parents and eye‑care professionals. As a result, manufacturers are under pressure to demonstrate not only efficacy but also refractive stability across all meridians. Against this backdrop, SightGlass Vision’s contrast‑modulation DOT lenses entered trials to test whether a different optical principle could avoid the astigmatism concern.

The recent CYPRESS (North America) and CATHAY (China) studies, each enrolling roughly 175 children aged 6‑13, compared DOT lenses with conventional single‑vision controls over a 12‑month period. Astigmatism prevalence shifted marginally—rising from 87 % to 92 % in the North American cohort and falling from 91 % to 88 % in the Chinese cohort—differences that were statistically insignificant. More compelling, axial length growth slowed by 0.15 mm in the U.S. group and 0.29 mm in the Chinese group, while spherical equivalent refractive error improved by 0.34 D and 0.54 D respectively. The lenses achieve these outcomes by subtly reducing contrast rather than adding peripheral power, a mechanism that appears neutral to astigmatic development.

For clinicians, the data provide a clear signal that DOT lenses can be prescribed without fearing an astigmatism penalty, expanding the therapeutic toolbox for myopia‑prone patients. The consistency of results across two geographically distinct populations also strengthens the case for broader market adoption, especially in regions where astigmatism prevalence is high. Industry analysts may view the findings as a catalyst for further investment in contrast‑management optics, while regulators will likely reference the studies when evaluating safety dossiers. Continued long‑term follow‑up will be essential, but the current evidence positions SightGlass DOT as a competitive alternative to peripheral‑defocus products.